RASSF1A and the Taxol Response in Ovarian Cancer

Overview

Journal Mol Biol Int

Publisher Hindawi

Specialty Molecular Biology

Date 2012 May 2

PMID 22548172

Citations 13

Authors

Susannah Kassler

Howard Donninger

Michael J Birrer

Geoffrey J Clark

Affiliations

Soon will be listed here.

Abstract

The RASSF1A tumor suppressor gene is frequently inactivated by promoter methylation in human tumors. The RASSF1A protein forms an endogenous complex with tubulin and promotes the stabilization of microtubules. Loss of RASSF1A expression sensitizes cells to microtubule destabilizing stimuli. We have observed a strong correlation between the loss of RASSF1A expression and the development of Taxol resistance in primary ovarian cancer samples. Thus, we sought to determine if RASSF1A levels could dictate the response to Taxol and whether an epigenetic therapy approach might be able to reverse the Taxol resistant phenotype of RASSF1A negative ovarian tumor cells. We found that knocking down RASSF1A expression in an ovarian cancer cell line inhibited Taxol-mediated apoptosis and promoted cell survival during Taxol treatment. Moreover, using a combination of small molecule inhibitors of DNA Methyl Transferase enzymes, we were able restore RASSF1A expression and Taxol sensitivity. This identifies a role for RASSF1A in modulating the tumor response to Taxol and provides proof of principal for the use of epigenetic therapy to overcome Taxol resistance.

Citing Articles

The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.

Song K, Artibani M Health Sci Rep. 2023; 6(5):e1235.

PMID: 37123549 PMC: 10140645. DOI: 10.1002/hsr2.1235.

The Hippo Signaling Pathway in Drug Resistance in Cancer.

Zeng R, Dong J Cancers (Basel). 2021; 13(2).

PMID: 33467099 PMC: 7830227. DOI: 10.3390/cancers13020318.

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.

Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V Cancers (Basel). 2019; 11(12).

PMID: 31766357 PMC: 6966477. DOI: 10.3390/cancers11121835.

Multidrug resistance affects the prognosis of primary epithelial ovarian cancer.

Gao B, Yang F, Chen W, Li R, Hu X, Liang Y Oncol Lett. 2019; 18(4):4262-4269.

PMID: 31579424 PMC: 6757297. DOI: 10.3892/ol.2019.10745.

The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.

Zhu Y, He D, Bo H, Liu Z, Xiao M, Xiang L Oncogene. 2019; 38(32):6065-6081.

PMID: 31273338 DOI: 10.1038/s41388-019-0858-7.

References

El-Kalla M, Onyskiw C, Baksh S . Functional importance of RASSF1A microtubule localization and polymorphisms. Oncogene. 2010; 29(42):5729-40. DOI: 10.1038/onc.2010.316. View

Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D . In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002; 21(24):6820-31. PMC: 139102. DOI: 10.1093/emboj/cdf682. View

Kuck D, Caulfield T, Lyko F, Medina-Franco J . Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther. 2010; 9(11):3015-23. DOI: 10.1158/1535-7163.MCT-10-0609. View

Hesson L, Cooper W, Latif F . The role of RASSF1A methylation in cancer. Dis Markers. 2007; 23(1-2):73-87. PMC: 3850810. DOI: 10.1155/2007/291538. View

Donninger H, Bonome T, Radonovich M, Pise-Masison C, Brady J, Shih J . Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004; 23(49):8065-77. DOI: 10.1038/sj.onc.1207959. View

Dallol A, Agathanggelou A, Fenton S, Ahmed-Choudhury J, Hesson L, Vos M . RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 2004; 64(12):4112-6. DOI: 10.1158/0008-5472.CAN-04-0267. View

Vos M, Dallol A, Eckfeld K, Allen N, Donninger H, Hesson L . The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2005; 281(8):4557-63. DOI: 10.1074/jbc.M512128200. View

Kreuzer K, Lass U, Bohn A, Landt O, Schmidt C . LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res. 1999; 59(13):3171-4. View

Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K . The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005; 20(2):645-63. DOI: 10.14670/HH-20.645. View

10.

Donninger H, Allen N, Henson A, Pogue J, Williams A, Gordon L . Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions. J Biol Chem. 2011; 286(21):18483-91. PMC: 3099665. DOI: 10.1074/jbc.M110.214874. View

11.

Pfeifer G, Dammann R, Tommasi S . RASSF proteins. Curr Biol. 2011; 20(8):R344-5. DOI: 10.1016/j.cub.2010.02.019. View

12.

Balch C, Yan P, Craft T, Young S, Skalnik D, Huang T . Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther. 2005; 4(10):1505-14. DOI: 10.1158/1535-7163.MCT-05-0216. View

13.

Donninger H, Vos M, Clark G . The RASSF1A tumor suppressor. J Cell Sci. 2007; 120(Pt 18):3163-72. DOI: 10.1242/jcs.010389. View

14.

Liu L, Tommasi S, Lee D, Dammann R, Pfeifer G . Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene. 2003; 22(50):8125-36. DOI: 10.1038/sj.onc.1206984. View

15.

Donninger H, Barnoud T, Nelson N, Kassler S, Clark J, Cummins T . RASSF1A and the rs2073498 Cancer Associated SNP. Front Oncol. 2012; 1:54. PMC: 3355887. DOI: 10.3389/fonc.2011.00054. View

16.

Agathanggelou A, Cooper W, Latif F . Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005; 65(9):3497-508. DOI: 10.1158/0008-5472.CAN-04-4088. View

17.

Ren J, Singh B, Huang Q, Li Z, Gao Y, Mishra P . DNA hypermethylation as a chemotherapy target. Cell Signal. 2011; 23(7):1082-93. DOI: 10.1016/j.cellsig.2011.02.003. View

18.

Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F . Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006; 66(5):2794-800. DOI: 10.1158/0008-5472.CAN-05-2821. View

19.

Vos M, Martinez A, Elam C, Dallol A, Taylor B, Latif F . A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 2004; 64(12):4244-50. DOI: 10.1158/0008-5472.CAN-04-0339. View

20.

Marquez V, Kelley J, Agbaria R, Ben-Kasus T, Cheng J, Yoo C . Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci. 2006; 1058:246-54. DOI: 10.1196/annals.1359.037. View